133 related articles for article (PubMed ID: 35393161)
1. Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11.
Wei Y; Zhu Y; Ye D
Eur Urol; 2022 Jul; 82(1):e14. PubMed ID: 35393161
[No Abstract] [Full Text] [Related]
2. Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11.
Turco F; Smith M; Omlin A; Gillessen S
Eur Urol; 2022 Jul; 82(1):e13. PubMed ID: 35469701
[No Abstract] [Full Text] [Related]
3. Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012.
von Eyben FE; Bauman G; Soydal C; Paganelli G
Eur Urol; 2020 Nov; 78(5):e201-e202. PubMed ID: 32222292
[No Abstract] [Full Text] [Related]
4. Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
von Eyben FE; Virgolini I; Roviello G
Eur Urol; 2018 Feb; 73(2):e31. PubMed ID: 28869068
[No Abstract] [Full Text] [Related]
5. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
Gillessen S; de Bono JS; Sartor O; Omlin AG
Eur Urol; 2018 Feb; 73(2):e32-e33. PubMed ID: 28869069
[No Abstract] [Full Text] [Related]
6. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Turco F; Armstrong A; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Bulbul M; Caffo O; Chi KN; Clarke C; Clarke N; Davis ID; de Bono J; Duran I; Eeles R; Efstathiou E; Efstathiou J; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; George D; Gleave M; Halabi S; Heinrich D; Higano C; Hofman MS; Hussain M; James N; Jones R; Kanesvaran R; Khauli RB; Klotz L; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ekeke Onyeanunam N; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin M; Ryan CJ; Saad F; Pablo Sade J; Sartor O; Scher HI; Shore N; Skoneczna I; Small E; Smith M; Soule H; Spratt D; Sternberg CN; Suzuki H; Sweeney C; Sydes M; Taplin ME; Tilki D; Tombal B; Türkeri L; Uemura H; Uemura H; van Oort I; Yamoah K; Ye D; Zapatero A; Gillessen S; Omlin A
Eur Urol; 2022 Jul; 82(1):6-11. PubMed ID: 35393158
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
Turco F; Armstrong A; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Bulbul M; Caffo O; Chi KN; Clarke C; Clarke N; Davis ID; de Bono J; Duran I; Eeles R; Efstathiou E; Efstathiou J; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; George D; Gleave M; Halabi S; Heinrich D; Higano C; Hofman MS; Hussain M; James N; Jones R; Kanesvaran R; Khauli RB; Klotz L; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ekeke ON; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Skoneczna I; Small E; Smith M; Soule H; Spratt D; Sternberg CN; Suzuki H; Sweeney C; Sydes M; Taplin ME; Tilki D; Tombal B; Türkeri L; Uemura H; Uemura H; van Oort I; Yamoah K; Ye D; Zapatero A; Gillessen S; Omlin A
Eur Urol; 2022 Jul; 82(1):e18-e19. PubMed ID: 35440417
[No Abstract] [Full Text] [Related]
8. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
Goonewardene SS; Persad R; Young A; Makar A
Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
[No Abstract] [Full Text] [Related]
9. Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Shen Y; Ye D
Eur Urol; 2012 Feb; 61(2):e3; author reply e4-5. PubMed ID: 21824719
[No Abstract] [Full Text] [Related]
10. Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes-A Report from a Consensus Meeting. Eur Urol 2015;67:771-7.
Kamrava M
Eur Urol; 2015 Jul; 68(1):e14. PubMed ID: 25703574
[No Abstract] [Full Text] [Related]
11. Re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 2013;64:372-8.
Froehner M
Eur Urol; 2014 Mar; 65(3):e41. PubMed ID: 24315704
[No Abstract] [Full Text] [Related]
12. Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive
Papa N; Perera M; Hofman MS; Bolton D; Lawrentschuk N
Eur Urol; 2017 Feb; 71(2):e66-e67. PubMed ID: 27597236
[No Abstract] [Full Text] [Related]
13. Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.
Sydes MR; Vale C; Kneebone A; Pearse M; Richaud P; Tierney JF; Parker CC
Eur Urol; 2012 Dec; 62(6):e99. PubMed ID: 23018161
[No Abstract] [Full Text] [Related]
14. Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.
Ghadjar P; Aebersold DM
Eur Urol; 2012 Apr; 61(4):e39. PubMed ID: 22169076
[No Abstract] [Full Text] [Related]
15. Reply to Michael Froehner's letter to the editor re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol 2013;64:372-8.
Nepple KG; Kibel AS
Eur Urol; 2014 Mar; 65(3):e42. PubMed ID: 24315707
[No Abstract] [Full Text] [Related]
16. Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
García Nader S; Peña Rodríguez S; Diaz Ritter CA
Eur Urol; 2023 Apr; 83(4):e103. PubMed ID: 36610879
[No Abstract] [Full Text] [Related]
17. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
Parker C; Sydes MR; Kynaston H;
Eur Urol; 2013 Nov; 64(5):e102. PubMed ID: 23953599
[No Abstract] [Full Text] [Related]
18. Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
Wassersug RJ; Schellhammer PF; Wibowo E
Eur Urol; 2024 Jun; 85(6):e173-e174. PubMed ID: 38538424
[No Abstract] [Full Text] [Related]
19. Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
Fanti S; Krause B; Weber W; Castellucci P; Grosu AL; de Jong IJ; Messa C; Picchio M; Pruim J; Langsteger W; Chiti A;
Eur Urol; 2011 Nov; 60(5):e37-8; author reply e39-41. PubMed ID: 21855205
[No Abstract] [Full Text] [Related]
20. Re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:340-51.
Park BK
Eur Urol; 2019 Sep; 76(3):e78. PubMed ID: 31186172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
